Market Place
Sourcing Support
All News #Library
Biotech
Rhythm Pharma To Release Q1 2026 Financial Results On May 5
09 Apr 2026 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals Announces Changes To Board Of Directors
03 Apr 2026 //
GLOBENEWSWIRE
Revolution, Ascendis Seen As Top Buyout Targets In Biopharma
19 Mar 2026 //
BIOSPACE
Rhythm Pharma To Join Guggenheim Biotech Summit
05 Feb 2026 //
GLOBENEWSWIRE
Rhythm Pharma Announces FDA Acceptance of sNDA for Setmelanotide
20 Aug 2025 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals to Report Q2 2025 Financial Results
22 Jul 2025 //
GLOBENEWSWIRE
Rhythm Pharma’s Bivamelagon Lowers BMI in Phase 2 Obesity Trial
09 Jul 2025 //
GLOBENEWSWIRE
Rhythm`s Obesity Pill Trial Hits Primary Goal, Sending Stock Up
09 Jul 2025 //
FIERCE BIOTECH
Rhythm Pharmaceuticals: Three Late-breaking Abstracts at ENDO
25 Jun 2025 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals Q1 2025 Financial Results & Update
07 May 2025 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals: Phase 3 trial meets BMI reduction goal
07 Apr 2025 //
GLOBENEWSWIRE
Rhythm Pharma Receives Expanded Imcivree for Obesity Treatment
03 Dec 2024 //
GLOBENEWSWIRE
Rhythm Pharma Publishes Phase 3 Setmelanotide Study Results
13 Nov 2024 //
GLOBENEWSWIRE
Rhythm: Setmelanotide Phase 2 Hypothalamic Obesity Data in Lancet
29 Apr 2024 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide
22 Feb 2024 //
GLOBENEWSWIRE
Rhythm Announces Completion of Screening for Enrollment in Setmelanotide Trial
04 Jan 2024 //
GLOBENEWSWIRE
Rhythm Presents Data from its Long-term Extension Study of Setmelanotide
17 Oct 2023 //
GLOBENEWSWIRE
Rhythm Announces Pre-Marketing Early Access Authorization for Setmelanotide
07 Aug 2023 //
GLOBENEWSWIRE
Rhythm Pharma Announces Health Canada Approval of IMCIVREE® Setmelanotide
08 May 2023 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.